Four out of five national US healthcare payers and nine of 16 regional payers said they were very concerned about the financial risk associated with gene therapies, according to a survey by the National Pharmaceutical Council and Analysis Group. However, their magnitude may be greater for gene therapy, creating potential for patient access restrictions or outright exclusions. The survey, which was conducted in March 2016, found that only one third of respondents thought it would be possible for patients who had received genetic therapies to receive them without any side effects. Almost all said payment would be dependent on performance-based requirements, while 95% said non-response to a treatment would be a 'deal breaker'.
Four out of five national US healthcare payers and nine of 16 regional payers said they were very concerned about the financial risk associated with gene therapies, according to a survey by the National Pharmaceutical Council and Analysis Group. The survey, which was conducted in March 2016, found that only one third of respondents thought it would be possible for patients who had received genetic therapies to receive them without any side effects. Almost all said payment would be dependent on performance-based requirements, while 95% said non-response to a treatment would be a 'deal breaker'.